JP2019517512A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517512A5 JP2019517512A5 JP2018563110A JP2018563110A JP2019517512A5 JP 2019517512 A5 JP2019517512 A5 JP 2019517512A5 JP 2018563110 A JP2018563110 A JP 2018563110A JP 2018563110 A JP2018563110 A JP 2018563110A JP 2019517512 A5 JP2019517512 A5 JP 2019517512A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- months
- ctla
- body weight
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 14
- 230000037396 body weight Effects 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000032818 Microsatellite Instability Diseases 0.000 claims 2
- 230000004075 alteration Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 101150061338 mmr gene Proteins 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 claims 1
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 claims 1
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 claims 1
- 101000738901 Homo sapiens PMS1 protein homolog 1 Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 229910015837 MSH2 Inorganic materials 0.000 claims 1
- 108010074346 Mismatch Repair Endonuclease PMS2 Proteins 0.000 claims 1
- 102100037480 Mismatch repair endonuclease PMS2 Human genes 0.000 claims 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 1
- 102000013609 MutL Protein Homolog 1 Human genes 0.000 claims 1
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 claims 1
- 102100037482 PMS1 protein homolog 1 Human genes 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 102000043321 human CTLA4 Human genes 0.000 claims 1
- 102000048362 human PDCD1 Human genes 0.000 claims 1
- 230000033607 mismatch repair Effects 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022155878A JP7721494B2 (ja) | 2016-06-03 | 2022-09-29 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
| JP2025093572A JP2025143276A (ja) | 2016-06-03 | 2025-06-04 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345662P | 2016-06-03 | 2016-06-03 | |
| US62/345,662 | 2016-06-03 | ||
| PCT/US2017/035822 WO2017210637A1 (en) | 2016-06-03 | 2017-06-02 | Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022155878A Division JP7721494B2 (ja) | 2016-06-03 | 2022-09-29 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019517512A JP2019517512A (ja) | 2019-06-24 |
| JP2019517512A5 true JP2019517512A5 (2) | 2020-07-16 |
Family
ID=59078186
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563110A Pending JP2019517512A (ja) | 2016-06-03 | 2017-06-02 | 結腸直腸癌を有する患者の処置における抗ｐｄ−１抗体の使用 |
| JP2022155878A Active JP7721494B2 (ja) | 2016-06-03 | 2022-09-29 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
| JP2025093572A Pending JP2025143276A (ja) | 2016-06-03 | 2025-06-04 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022155878A Active JP7721494B2 (ja) | 2016-06-03 | 2022-09-29 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
| JP2025093572A Pending JP2025143276A (ja) | 2016-06-03 | 2025-06-04 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11332529B2 (2) |
| EP (2) | EP3988570A1 (2) |
| JP (3) | JP2019517512A (2) |
| KR (3) | KR102702675B1 (2) |
| CN (1) | CN109476754A (2) |
| ES (1) | ES2897964T3 (2) |
| WO (1) | WO2017210637A1 (2) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1203971A1 (en) * | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| KR20230030022A (ko) | 2014-11-13 | 2023-03-03 | 더 존스 홉킨스 유니버시티 | 관문 차단 및 미소부수체 불안정성 |
| KR20250004095A (ko) * | 2015-04-17 | 2025-01-07 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물 |
| JP2018514550A (ja) | 2015-04-28 | 2018-06-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| EP4458417A3 (en) | 2015-08-11 | 2025-02-19 | Wuxi Biologics Ireland Limited | Novel anti-pd-1 antibodies |
| US10392442B2 (en) | 2015-12-17 | 2019-08-27 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
| JP2019517512A (ja) | 2016-06-03 | 2019-06-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 結腸直腸癌を有する患者の処置における抗ｐｄ−１抗体の使用 |
| CA3084370A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| JP2021513540A (ja) * | 2018-02-13 | 2021-05-27 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗ｐｄ−１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法 |
| WO2020033283A1 (en) * | 2018-08-09 | 2020-02-13 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer with a combination of programmed death receptor (pd-1) antibodies and vicriviroc |
| AU2019337547A1 (en) * | 2018-09-13 | 2021-03-18 | Merck Sharp & Dohme Llc | Combination of PD-1 antagonist and LAG3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer |
| KR20210146348A (ko) * | 2019-03-28 | 2021-12-03 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| GB201912107D0 (en) * | 2019-08-22 | 2019-10-09 | Amazentis Sa | Combination |
| CN110656179A (zh) * | 2019-10-29 | 2020-01-07 | 至本医疗科技（上海）有限公司 | 免疫敏感性预测的生物标志组成物及用途、试剂盒设备存储介质 |
| AR122043A1 (es) * | 2020-05-12 | 2022-08-03 | Bristol Myers Squibb Co | Dosificación y administración del anticuerpo anti-ctla-4 activable |
| CN115569193B (zh) * | 2021-10-09 | 2024-04-02 | 施慧达药业集团(吉林)有限公司 | 戈氏梭菌芽孢联合帕博利珠单抗的应用及治疗结肠癌药物和戈氏梭菌芽孢冻干粉制备方法 |
| CN120731227A (zh) * | 2022-10-31 | 2025-09-30 | 艾吉纳斯公司 | 使用抗ctla4抗体治疗结直肠癌的方法 |
| JP2026506594A (ja) * | 2023-02-09 | 2026-02-25 | アンボーゲン セラピューティクス インコーポレイテッド | 大腸癌の治療のための医薬キット及びその使用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| JP2003520828A (ja) | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート，エルエルシー | Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用 |
| EP1340819A1 (en) | 2002-02-28 | 2003-09-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Microsatellite markers |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| CN1845991A (zh) * | 2003-08-29 | 2006-10-11 | 田中纪章 | 核酸扩增用引物以及利用该引物检查结肠癌的检查方法 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| CA2828940C (en) | 2011-03-10 | 2024-04-16 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| FI20115709A0 (fi) | 2011-07-01 | 2011-07-01 | Helsingin Yliopisto | Menetelmä perinnöllisten syöpien diagnosointiin |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| SMT202100065T1 (it) | 2013-05-02 | 2021-03-15 | Anaptysbio Inc | Anticorpi diretti contro la proteina della morte programmata (pd-1) |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| WO2015116868A2 (en) * | 2014-01-29 | 2015-08-06 | Caris Mpi, Inc. | Molecular profiling of immune modulators |
| KR20230030022A (ko) * | 2014-11-13 | 2023-03-03 | 더 존스 홉킨스 유니버시티 | 관문 차단 및 미소부수체 불안정성 |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| US10995140B2 (en) * | 2015-06-05 | 2021-05-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | GM-CSF/CD40L vaccine and checkpoint inhibitor combination therapy |
| JP2019517512A (ja) | 2016-06-03 | 2019-06-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 結腸直腸癌を有する患者の処置における抗ｐｄ−１抗体の使用 |
| WO2018183408A1 (en) * | 2017-03-31 | 2018-10-04 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer with a combination of an antagonist of pd-1 and an anti-ctla4 antibody |
-
2017
- 2017-06-02 JP JP2018563110A patent/JP2019517512A/ja active Pending
- 2017-06-02 EP EP21197402.7A patent/EP3988570A1/en active Pending
- 2017-06-02 ES ES17731359T patent/ES2897964T3/es active Active
- 2017-06-02 KR KR1020237010151A patent/KR102702675B1/ko active Active
- 2017-06-02 KR KR1020187038115A patent/KR102515509B1/ko active Active
- 2017-06-02 CN CN201780048328.2A patent/CN109476754A/zh active Pending
- 2017-06-02 US US16/306,290 patent/US11332529B2/en active Active
- 2017-06-02 WO PCT/US2017/035822 patent/WO2017210637A1/en not_active Ceased
- 2017-06-02 KR KR1020247029228A patent/KR20240134249A/ko active Pending
- 2017-06-02 EP EP17731359.0A patent/EP3464373B1/en not_active Revoked
-
2022
- 2022-04-19 US US17/724,399 patent/US20220356254A1/en not_active Abandoned
- 2022-09-29 JP JP2022155878A patent/JP7721494B2/ja active Active
-
2024
- 2024-07-29 US US18/787,822 patent/US20250026831A1/en active Pending
-
2025
- 2025-06-04 JP JP2025093572A patent/JP2025143276A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517512A5 (2) | ||
| CN108289892B (zh) | 治疗组合物、组合和使用方法 | |
| JP2018500332A5 (2) | ||
| JP2019503387A5 (2) | ||
| JP2014533279A5 (2) | ||
| TWI890661B (zh) | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法 | |
| JP2018518454A5 (2) | ||
| JP2018522887A5 (2) | ||
| JP2018516966A5 (2) | ||
| FI3932951T3 (fi) | Menetelmiä ihosyövän hoitamiseksi antamalla PD-1-inhibiittoria | |
| JP2018516969A5 (2) | ||
| IL313952A (en) | Combination of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies for cancer treatment | |
| JP2019519499A5 (2) | ||
| JP2021528423A5 (2) | ||
| JP2019515008A5 (2) | ||
| JP2020502271A5 (2) | ||
| JP2017501167A5 (2) | ||
| JP2016536314A5 (2) | ||
| JP2015534577A5 (2) | ||
| JP2019517512A (ja) | 結腸直腸癌を有する患者の処置における抗ｐｄ−１抗体の使用 | |
| JP2017514795A5 (2) | ||
| JP2019517511A5 (2) | ||
| JP2017502017A5 (2) | ||
| JP2019517498A5 (2) | ||
| JP2012102122A5 (2) |